Key Takeaways
- • EQT has agreed a deal valued at €10.8bn to take Qiagen, the Dutch life science tools and diagnostics company listed in Frankfurt and New York, private, according to PEI Private Equity.
- • The offer carries a 40.3% premium, a key term for shareholders evaluating the transaction.
- • The take-private positions the asset within EQT's private equity portfolio in the life sciences tools and diagnostics sector.
- • Source material for this story is limited to headline-level details, so terms beyond price and premium, including financing structure and closing timeline, are not confirmed here.
Summary
EQT has struck a €10.8bn deal to take Qiagen private, according to PEI Private Equity. The transaction values the Dutch life science tools and diagnostics company at a 40.3% premium to its prior trading price, a figure that signals the price needed to secure board and shareholder support for a delisting from Frankfurt and New York.
Qiagen is a Dutch life science tools and diagnostics company with a dual listing in Frankfurt and New York. A take-private of this scale moves a publicly traded diagnostics business into private ownership, removing it from public market disclosure requirements and shifting governance to the buyer.
The deal is a notable example of large-cap private equity activity in the life sciences tools sector, where sponsors have pursued diagnostics and tools assets as recurring-revenue franchises. Further details on financing, regulatory approvals, and expected closing timing were not available in the source material reviewed for this summary.
Qiagen is a Dutch life science tools and diagnostics company with a dual listing in Frankfurt and New York. A take-private of this scale moves a publicly traded diagnostics business into private ownership, removing it from public market disclosure requirements and shifting governance to the buyer.
The deal is a notable example of large-cap private equity activity in the life sciences tools sector, where sponsors have pursued diagnostics and tools assets as recurring-revenue franchises. Further details on financing, regulatory approvals, and expected closing timing were not available in the source material reviewed for this summary.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.